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The human thioredoxin system has a wide
range of functions in cells including regulation of
cell proliferation and differentiation, immune
system modulation, antioxidant defense, redox
control of transcription factor activity, and
promotion of cancer development. A key
component of this enzymatic system is the
selenoprotein thioredoxin reductase 1 (TrxR1),
encoded by the TXNRD1 gene. Transcription of
TXNRD1 is subjected to extensive alternative
splicing, leading to a number of transcripts also
encoding isoforms of TrxR1 that differ from
each other at their N-terminal domains. Here we
have studied the TXNRD1_v3 isoform containing
the atypical N-terminal glutaredoxin (Grx)
domain. Expression of the transcript of this
isoform was found predominantly in testis but
was also detected in ovary, spleen, heart, liver,
kidney and pancreas. By immunohistochemical
analysis in human testis with antibodies specific
for the Grx domain of TXNRD1_v3 the protein
was found to be predominantly expressed in the
Leydig cells. Expression of the TXNRD1_v3
transcript was also found in several cancer cell
lines (HCC1937, H23, A549, U1810 or H157),
and in HeLa cells it was induced by estradiol
or testosterone treatments. Surprisingly, GFP
fusions with the complete TXNRD1_v3 protein
or with only its Grx domain localized to
distinct cellular sites in proximity to actin and
furthermore, had a potent capacity to rapidly
induce cell membrane protrusions. Analyses of
these structures suggested that the Grx
domain of TXNRD1_v3 localizes first in the
emerging protrusion and is then followed into
the protrusions by actin and subsequently by
tubulin. The results presented here thus reveal
that TXNRD1_v3 has a unique and distinct
expression pattern in human cells and suggest
that the protein can guide actin
polymerization in relation to cell membrane
restructuring.
INTRODUCTION
The thioredoxin system involves several
thioredoxins (Trx1) and thioredoxin reductases
(TrxR) that are found in different cellular and
subcellular locations where they participate in a
wide range of functions in cells, including
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protection from oxidative stress, synthesis of DNA
precursors, regulation of cell proliferation and
differentiation, control of apoptosis, modulation of
the immune system, redox control of transcription
factor activity and promotion of cancer
development (1-6). The many functions of the
thioredoxin system are mainly carried out by the
interaction of thioredoxins with target proteins,
most often involving redox reactions whereby
thioredoxin reduces a disulfide in the target protein.
For this purpose, the active site disulfide
thioredoxin has first to be reduced to a dithiol,
which is catalyzed by TrxR using NADPH, and
hence, making TrxR a key player for essentially all
downstream cellular functions regulated by the
thioredoxin system.
In human cells, three genes encode
thioredoxin reductases, namely TXNRD1, TXNRD2
and T X N R D 3 . The classical TrxR1 enzyme,
encoded by the TXNRD1 gene, is predominantly
cytosolic and is expressed in most, if not all, human
cells, where Trx1 is believed to be its major
substrate (4,5,7,8). The TXNRD2 gene encodes
mitochondrial TrxR2 that reduces mitochondrial
Trx2 (9-11) although TrxR2 is also found in the
cytosol (12) but seems to have non-ubiquitous
lower expression level compared to TrxR1 (see (13)
and www.proteinatlas.org). Both cytoplasmic and
mitochondrial thioredoxin systems are essential for
mammals, as shown by the embryonic lethal
phenotypes of the respective knockout mice
(14,15). Thioredoxin reductases TrxR1 and TrxR2
a r e  b o t h  homodimeric selenoprotein
oxidoreductases containing FAD and having a
carboxylterminal –Gly-Cys-Sec-Gly active site
motif (where Sec is selenocysteine), which is
providing the thioredoxin-reducing activity (16-21).
The thioredoxin reductase isoenzyme TGR,
encoded by the TXNRD3 gene, is similar to TrxR1
and TrxR2, but contains an additional monothiol
Grx domain as an N-terminal addition to the TrxR-
module. The TGR enzyme is mainly expressed in
early spermatids in testis and is suggested to
participate in the redox reactions required during
maturation of sperm (22-24).
All three human thioredoxin reductase genes
are subject to extensive splicing, mainly in the 5’-
end, leading to a number of transcripts that in
several cases encode different protein isoforms
(7,8,12,25,26). In the present study, we have
characterized further a rare alternative transcript
derived from the TXNRD1 gene that expresses an
atypical N-terminal Grx domain fused to the
TrxR1 module and encoded by alternative exons
located upstream of the core promoter. Adhering
to the generally proposed nomenclature for
human genes, we originally named the transcript
b1 and its encoded protein isoform TXNRD1_v3
(7) and will keep to this nomenclature in the
present paper. For ease of readability, the
TXNRD1_v3 protein is hereafter referred to as
version three (“v3”) of TrxR1. In Scheme 1, the
exon organization of the 5’-region of the v3
transcript is depicted and compared to the other
main isoforms of human TrxR1, with the
localization of the different primers and probes
used in this study also shown in the scheme.
The Grx domain of v3 has an atypical
CTRC active site sequence (7,25), instead of the
more common CPYC motif found in Grx’s (27).
This Grx domain of v3 was earlier found to lack
activity in any of the classical Grx assays, except
if the CTRC active site was mutated to the
classical CPYC motif whereupon the protein
gained typical Grx activity (25). The rare cDNA
or EST clones found to be encoding v3 have thus
far only been derived from testis (7,25).
Interestingly, the transcripts encoding this
isoform can be found only in human, chimpanzee
and dog, but not in mouse or rat (25).
Furthermore, expression of the v3 protein was
recently detected in a human mesothelioma cell
line using immunoblotting and mass spectrometry
(28). To date, no information exists about the
possible function(s) of v3 in human cells, which
has been the focus of the present study.
EXPERIMENTAL PROCEDURES
Northern blot analysis
Human multiple tissue Northern blots with
poly(A+) RNA from different tissues were
purchased from Clontech. A PCR fragment
composed of the three first exons of the Grx
domain of the TXNRD1_v3 was labeled with [α-
32P]dCTP (Rediprime random primer labeling kit;
Amersham Pharmacia Biotech) and hybridized at
65°C overnight in ExpressHyb Solution
(Clontech) following the protocol. The blots were
also hybridized with human glyceraldehyde-3-
phosphate dehydrogenase as control. The blots
were scanned and quantified with the Gel Pro
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Analyzer program (Media Cybernetics).
PCR analyses
First strand cDNA panels from various
tissues were obtained from Clontech. The β1
variant cDNA cloned into a pET vector (Novagen)
served as a positive control when used as template
in the PCR reactions. The cDNA of the different
cancer cell lines used here was generously provided
by Christopher Horst Lillig and Maria Lönn
(Karolinska Institutet). The following primers were
used: R5, 5’-GCA ACC CAC ATT CAC ACA
TGT TCC TCC-3’; R2, 5’-GGA CCA TGG CCG
CCT ATC TTT CTC TGT TTC ACA AAC
AC-3’; FI, 5’-GAG TCC TGA AGG AGG GCC
TGA TGT CTT CAT CAT TCT C-3’; and
Fβ-VIII, 5’-CAA GCA CAA AAT AAG GAA CAC
ACA GAG ATT TAA ATA ACA G-3’. For PCR
reactions 2.5 U/reaction Taq polymerase, 10 µM of
each primer and 2-3 µl cDNA template were used.
Reactions were heated to 96°C for 1 min before the
first of 35 cycles (94°C for 30 sec, 58°C for 45 sec
and 72°C for 2 min) followed by 72°C for 3 min
after the final cycle and then paused at 4°C. PCR
products were analyzed on 1.2% agarose gels with
5 µl sample loaded. Sequencing reactions of some
DNA bands were performed to verify the sequence
of PCR products.
Immunohistochemistry
Paraffin-embedded testis tissue slides
(ProSci) were de-waxed and rehydrated by placing
the slides in three changes of xylene for 3 min each
time followed by three changes of ethanol (99.5%
for 2x5 min, 95% for 2x4 min) 70% for 1x5 min)
and then hydrated at 37°C for 3 min. For antigen
retrieval, slides were immersed into a solution of
pH 7.8 containing 0.1 g CaCl2 and 0.1 g
chymotrypsin (from bovine pancreas) in water at
37°C. After removing the slides, they were placed
in cold water and rinsed twice with TBS containing
0.025% Triton X-100. Slides were blocked in 10%
normal goat serum (DAKO) with 1% BSA in TBS
for 2 h at RT, subsequently drained and wiped
around the sections. Polyclonal rabbit antibodies,
α-TXNRD1_v3 (α-v3), were made by AgriSera
against the synthetic v3-derived peptide (NH2-
CKGKNGDGRRWSAKDHHPGK-COOH), with
the underlined cysteine residue added for
maleimide-linked conjugation of keyhole limpet
hemocyanin protein as immunization carrier. The
peptide sequence is encoded by exons β-VIII and β-
VI (see Scheme 1). The antibodies were eluted at
pH 7.0 from affinity purified rabbit IgG and kept
in PBS with 20% glycerol (0.497 mg/ml) and
used as primary antibodies. The slides were
incubated overnight at 4°C with a 1:200 dilution
of α-v3 primary antibodies in 200 µl TBS with
1% BSA. For the pre-absorption control, the
same synthetic peptide antigen (500 µg) used for
raising the antibodies was added to the primary
antibody solution. Subsequently, the slides were
rinsed for 2x5 min in TBS with 0.025% Triton X-
100. Slides were incubated for 2 h at RT with
biotinylated goat α-rabbit secondary antibody
(DAKO) in a 1:200 dilution in TBS containing
1% BSA. Slides were rinsed for 2x5 min in TBS.
Streptavidin antibody complexed with
horseradish peroxidase (DAKO) were applied to
the slides in TBS for 30 min at RT. Slides were
rinsed 2x5 min with TBS and developed with
chromogen (DAB, DAKO) for 10 min at RT.
Following another rinse under running tap water
for 5 min, slides were counterstained with
Mayer’s hematoxylin (DAKO) for 2 min. Then,
slides were rinsed with water and counterstained
with eosin for 2 sec, rinsed again with water and
finally mounted using fluorescent mounting
medium (DAKO).
Transfection experiments
TXNRD1_v3-GFP, v3(Grx)-GFP or TrxR1
module-GFP fusion constructs were made using a
human EST clone for TXNRD1_v3 (Genbank
accession number BG772375) as template for
PCR. The following forward primers were used:
Grx-TrxR1 GFP Forward, CTG AAT TCG CCA
CCA TGG GCT GCG CCG or TrxR1 GFP
Forward, CTG AAT TCG CCA CCA TGG ACG
GCC CTG (both introducing an Eco RI site and
designed for construction of a Kozac sequence) in
combination with the following reverse primer:
Grx/TrxR1 GFP Reverse, ATG GAT CCG CAG
CCA GCC TGG AG (introducing a Bam HI site).
Cloning of the final desired target constructs for
transfection experiments was made using the
pEGFP-N3 vector (Clontech), fusing the GFP at
the carboxylterminal end of the protein domains
and for the TrxR1 module-encoding transcripts
excluding both the selenocysteine residue and the
3’-untranslated region of the cDNA, essentially
as described previously (29). HEK293 and MCF7
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cells were grown on glass cover slips until they
reached ~80% confluency. Subsequently, cells were
transfected with the constructs using lipofectamine
2000 (Invitrogen) according to manufacturer’s
instructions. We used various concentrations of
DNA ranging from 0.25 to 1 µg per well on a six
well plate, without any differences observed. Cells
were fixed 16 hours after transfection in 4%
paraformaldehyde for 30 minutes at room
temperature and then permeabilized with PBS-T
(PBS with 0.1% Tween 20) for 3x5 min washes,
followed by a blocking step using 5% normal goat
serum (Jackson ImmunoResearch Laboratories) in
PBS-T. Subsequently, after a short wash in PBS-T
cells were incubated with a monoclonal anti-β-
tubulin antibody (T4026, Sigma) diluted 1:200 in
PBS-T for 1 hour followed by 3x5 min washes. The
tubulin antibody was detected using a goat anti
mouse antibody conjugated to Alexa Fluor 568
(Molecular Probes) diluted 1:500 while the actin
network was visualized using phalloidin Alexa
Fluor 647 (Molecular Probes) diluted 1:40 in PBS-
T. After a 1-hour incubation cells were washed
briefly and stained with DAPI (Molecular Probes)
for 5 min and then washed 3x5 min in PBS-T
before mounting using fluorescence mounting
media (Callbiochem). For co-staining of ERα and
ERβ, cells were treated with 10 nM estradiol and
stained essentially as described before (29).
Fluorescence microscopy
For the imaging we employed a Leica AS MDW
fluorescence microscope (Leica microsystems).
DAPI, GFP and Alexa Fluor 568 were excited and
fluorescence detected using a triple band-pass filter
cube (Leica microsystems) with the excitation
wavelengths/band-pass of 420/30, 495/12, 570/20
and the emission wavelengths/band-pass of 465/20,
530/30 and 640/40. Separation of the fluorophores
was achieved by adjusting the excitation
wavelength of the monochromator. For the
phalloidin Alexa Fluor 647 a separate filter was
used, a Cy5 filter (Chroma) with excitation and
emission wavelengths of 620/60 and 700/75. Image
stacks were obtained with a step size of 0.25 µm in
the z-direction and then deconvolved using
AutoQuant’s blind deconvolution algorithm.
Images were then pseudocolored and prepared in
Photoshop software (Adobe). The live cell
experiments were performed using the AS MDW as
well, with the difference that the z-stacks obtained
had a 0.5 µm step size. For production of the
movie, the transfected cells were followed for 1
hour with a z-stack obtained every minute and
were deconvolved as previously described and
composed into a single file.
RESULTS
Expression of v3 in human tissues and cells
As the human v3 transcript has only been
identified from rare EST clones and partial PCR
amplifications (7,25), we first aimed to analyze
the complete size of the v3 transcript and its
expression pattern in different human tissues
using Northern blot. For this purpose, we used a
v3-specific probe containing the first three exons
of the Grx domain which are unique to this
variant (red in Scheme 1). This analysis showed a
single transcript of ~4.5 kb size in testis, while all
other analyzed tissues were negative (Fig 1A).
This size fits very well with the expected size of
the β1 transcript, encoding the TrxR1 module
plus the N-terminal Grx domain. Next, using
specific PCR analyses with first-strand cDNA,
we also found v3 transcript in samples from
ovary, spleen, heart, liver, kidney and pancreas in
addition to that of testis, but could not detect the
transcript in thymus, prostate, small intestine,
colon, leukocyte, brain, placenta, lung or skeletal
muscle (Fig 1B). The PCR product obtained
corresponded to the expected size of 468 bp (see
Scheme 1) and its specificity was verified by
sequencing of the PCR products from testis and
ovary. Given that testis was the tissue with by far
the highest amount of v3 mRNA, we set up to
analyze the v3 protein expression pattern in testis
by using specific polyclonal antibodies raised
against the N-terminal Grx domain of v3,
encoded by exons β-VIII and β-VI (see Scheme 1).
Immunohistochemical staining of human testis
using these antibodies identified interstitial
Leydig cells as the most prominent cell type
expressing v3 (Fig 1C). This should be compared
to the staining of Leydig cells, Sertoli cells and
spermatids using a commercial antibody against
the TrxR1 module as published by others (see
(13) and www.proteinatlas.org; Fig 1E and F).
We subsequently analyzed the expression
of the v3 transcript in human cancer cell lines
using the same PCR strategy as described for
normal tissue (see Scheme 1). Several cancer cell
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lines were found to express v3, i.e. HCC1937, H23,
A549, U1810, U1285, and H157 (Fig 2A). Other
cell lines, such as U1285, HeLa or Jurkat, were
negative in the analysis. Interestingly, HeLa cells
that normally did not express v3 induced the
transcript upon treatment with estradiol or
testosterone, while other treatment such as serum
starvation or hydroxyurea had no obvious effect on
the expression (Fig 2B).
Localization of TXNRD1_v3 in transfected
cells
Human TXNRD1_v2 has been shown to co-
localize with the estrogen receptors ERα  and ERβ
in the nucleus of transfected cells in the presence of
ligand (29). Because of the effect of estradiol and
testosterone on v3 expression (Fig 2B) and since
the last exon of the Grx domain of v3 is shared with
a part of TXNRD1_v2 (Scheme 1), we analyzed
whether v3 would also co-localize with estrogen
receptors in transfected cells. As shown in Figure
3A and 3B we found no evidence of such co-
localization in transfected HEK293 cells of a v3-
GFP fusion protein with either the ERα (Fig 3A) or
the ERβ (Fig 3B) nuclear receptors in the presence
of ligand. However, performing these experiments
we noted a strikingly dotted appearance of the v3-
GFP fusion protein fluorescence (Fig 3A and B).
We thus analyzed that pattern in further detail,
using GFP fusion constructs either with the
complete v3 protein, the TrxR1 module alone or the
Grx domain of v3 alone, also comparing their
respective pattern of localization to that of actin and
tubulin. This approach showed that all constructs
containing the Grx domain of v3 display a dotted
cytosolic appearance as well as membrane
associated fluorescence in the two cell lines used
(HEK293 and HeLa) (Fig 4A, C and F). This could
not be seen with neither the TrxR1 module alone in
fusion with GFP, which showed a more diffuse
cytosolic localization (Fig 4D), nor with only GFP
alone, which was used as control and found in both
cytosol and nucleus in these cells (Fig 4B and E).
In a mitotic cell, fluorescence of the GFP-coupled
Grx domain of v3 appeared strongly localized to
the cell membrane (Fig 4G). Comparing the
localization of the Grx domain of v3 fused to GFP
with the staining patterns of actin and tubulin in the
same cells, it was clear that the Grx domain of v3
(either when expressed as the complete protein
carrying the TrxR1 module or in the form of the
isolated Grx domain) closely resembled the
staining of actin, but without a complete overlap.
Comparing the green fluorescence of the v3-
derived GFP fusion proteins with the red staining
of actin and analyzing the merged figures, it
seemed like the green fluorescence was more
pronounced at the cell membrane, while in the
case of the dotted cytosolic staining the actin-
derived staining was more pronounced than the
fluorescence of v3, although a clear overlap
(yellow in the merged pictures) could be seen
(Fig 4A, C, F and G).
Induction of cell membrane protrusions
While performing the localization
experiments shown in Figure 4, we noted that the
cells transfected with GFP in fusion with the Grx
domain of v3 (either alone or followed by the
TrxR module) not only showed a dotted or
membrane-associated pattern of fluorescence, but
also gained a novel phenotype consisting of a
strong tendency to form cell membrane
protrusions. Interestingly, these protrusions
displayed green fluorescence, suggesting that the
Grx domain of v3 is directly involved in driving
the formation of these novel structures.
Analyzing one of the protrusions in more detail
(Fig 4C, dashed white box, merged picture),
we observed that the v3-derived fluorescence
appeared to be present in the whole membrane
protrusion (Fig 5A) similarly to what is seen with
actin staining (Fig 5B), while tubulin staining
was mainly detected at the base of the protrusion
(Fig 5C). The merged figure clearly showed that
a smaller protrusion at the side of the major
protrusion was only fluorescent for v3 (Fig 5D).
Using computer analyses of a three-dimensional
isosurface model from a AS MDW fluorescence
microscope, it appeared clear that the v3-derived
green fluorescence in fact seemed to “lead” the
formation of membrane protrusions, with the red
stained actin following the protrusion and tubulin
growing last into the newly formed structure (Fig
5E). Indeed, we noted that cells transfected with
a construct expressing the Grx domain of v3,
either alone or in fusion with the TrxR1 module,
displayed rapid formation of dynamic cell
membrane protrusions. This is further illustrated
in a time-lapse movie (Movie 1, provided as
supplemental data on JBC On-line).
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DISCUSSION
Here we found that the third splice variant of
human TrxR1, v3, exhibits a prominent expression
in Leydig cells of the testis and is expressed in a
few additional tissues including ovary and several
cancer cell lines. Its expression in HeLa cells may
be induced by treatment with steroid sex hormones.
We also found that the Grx domain of v3 seems to
induce actin and tubulin polymerization, thus
promoting a prominent formation of cell membrane
protrusions. These findings suggest that v3 is a
uniquely specialized splice variant of TrxR1. This
adds further complexity to the human thioredoxin
system and gives rise to a number of questions
regarding both the molecular mechanisms for
regulation of expression of v3 and the potential role
of this splice variant for human cell function.
The transcripts for mammalian thioredoxin
reductase isoenzymes are known to display
significant alternative splicing in the 5’-region,
resulting in some cases in alternative N-terminal
domains of the encoded protein (7,8,12,25,26,29-
31). The capacity to induce cell membrane
protrusions as found here is, however, the hitherto
first demonstrated function of the Grx domain
encoded by the v3 transcript. Prior knowledge of
the v3 transcript included its expression in testis
(7,25), which was here shown to be predominantly
derived from the Leydig cells. It was also shown
earlier that the v3 transcript is present in human,
chimpanzee and dog (where also the encoded
protein was demonstrated using testis extract) but it
is not found in mouse or rat (25). The human v3
protein was also recently demonstrated to be
expressed in human mesothelioma cells (28). The
encoded Grx domain of v3 lacks classical
glutaredoxin activity and, interestingly, it
furthermore inhibits the inherent thioredoxin
reductase activity of the TrxR1 module to which it
is fused (25).
The presently available results regarding v3
suggest that its functions in cells may be highly
specialized. Based on the transfection experiments
shown herein, the protein was found to catalyze cell
membrane restructuring with promotion of actin
polymerization. Such properties may reflect a role
in certain cell type-related growth conditions and
could, possibly, be related to cellular transport
functions. The role of v3 may also be related to
steroid sex hormone signaling considering the
strong expression in Leydig cells and its
induction in HeLa cells upon steroid treatment.
Many questions are yet unanswered, but certain
considerations can be made regarding the
potential relations between v3 and the membrane
protrusions here found to be provoked by this
protein. It is well known that the polymerization
and functions of actin or tubulin are redox
regulated and earlier experiments have also
demonstrated links to the glutathione and
thioredoxin systems, shortly summarized as
follows. For more than 15 years, tubulin has been
recognized as a protein with reactive sulfhydryl
groups, the assembly of which may be regulated
by the thioredoxin (32,33) or glutaredoxin system
(34). It was also shown that deglutathionylation
of Cys-374 in actin increases its polymerization
potency in relation to EGF signaling and that this
deglutathionylation is catalyzed by glutaredoxin
(35). This effect was further demonstrated to
have a physiological function using siRNA for
knockdown of Grx1, which hampered actin
polymerization and translocation close to the cell
membrane in NIH 3T3 cells (36). It should be
noted that those results may be seen as
resembling or strengthening the findings
presented in our study, but that knockdown of
Grx1 (36) should presumably not affect v3
expression. These results indicate that different
glutaredoxin isoforms may have either redundant
function in relation to actin polymerization or
rather highly specified such functions in relation
to cell type or growth stimuli. The structural basis
for redox regulation of actin was also recently
delineated in further detail, showing the
importance of both Cys-374 and Cys-272 in actin
and paving the way for more detailed studies of
actin regulation in relation to redox active
proteins (37). It should be emphasized that
although we found in this study a prominent
capacity of v3 to induce actin polymerization and
cell membrane protrusions the protein is, as
already mentioned, inactive in regular
glutaredoxin assays (25). It may be possible that
it has a restricted substrate specificity interacting
only with actin or some actin-associated
protein(s). We have tried to measure its activity
in vitro with actin polymerization assays but
hitherto without findings of any such activity
(unpublished observations) and the molecular
basis for the cellular effects reported here must
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therefore await further studies.
It was surprising to us that v3 was expressed
in the Leydig cells of the testis. Several unique
members of the thioredoxin system are known to be
expressed in testis, including TGR (22), Txl-2 3
(38), and Sptrx-1, -2, and -3 expressed specifically
in sperm (39-41). None of these other proteins,
however, are being prominently expressed in the
Leydig cells (42). What could the function of v3 be
in the Leydig cells? It could be noted that testicular
macrophages and the Leydig cells seem to be
functionally coupled with the macrophages
stimulating testosterone secretion by the Leydig
cells and physically interacting by membrane
projections from the Leydig cells being located
within membrane invaginations of the
macrophages, at least in rat testis (43). Specific
structures of actin are also involved in the
clustering of the Leydig cells around blood vessels
(44). Perhaps v3 could be involved in keeping the
integrity or forming such structural components
required for Leydig cell function. It is also
noteworthy that we found v3 expression to be
induced in HeLa cells by testosterone or estradiol,
suggesting that v3 could also be involved in
pathways related to the testosterone synthesis or
secretion by the Leydig cells of the testis or similar
sex hormone-related functions in the ovary. It
should be noted, however, that v3 did not co-
localize with estrogen receptors in the nucleus, in
contrast to the second splice isoforms of TrxR1,
TXNRD1_v2 (29). It should also be noted that,
similarly to the earlier study of TXNRD1_v2 (29),
we performed those analyses using constructs
lacking the selenocysteine residue of the TrxR1
module. These localization studies lead us to the
finding that the Grx domain of v3 by itself can
promote cell membrane protrusions, thereby
evidently being a function not dependent upon the
integrity of the selenocysteine residue in the TrxR1
module of v3. It is not possible to exclude,
however, that the Grx domain of v3 can interact
with endogenous selenocysteine-containing TrxR1
expressed in the transfected cells, which needs to be
analyzed in future studies. It is also possible that
some naturally expressed transcripts indeed encode
the Grx domain of v3 without fusion to the
complete TrxR1 module, as may be suggested by
many incomplete EST clones found in Genbank.
This is another factor that should be analyzed in
future studies.
The expression of v3 in a number of cancer
cells as found here is of potential interest in
relation to actin polymerization, with possible
importance for cell mobility or invasiveness,
which should also be the focus of future studies.
Moreover, since the expression of v3 is regulated
by an alternative promoter located upstream of
the core promoter, which is otherwise guiding
expression of the more common TrxR1 splice
variants (7,31), this alternative promoter should
be studied in terms of its transcriptional
mechanisms.
To conclude, this study is the most detailed
study thus far regarding the tissue specific
expression of the third splice variant of human
TrxR1, discovering the highest expression in
Leydig cells of the testis and a steroid sex
hormone-responsive induction in a cancer cell
line otherwise not expressing this splice variant.
Ovary and several other cancer cell lines also
expressed the transcript, without hormone
treatment. This study is also the first to show a
function of the Grx domain of this v3 splice
variant using transfection experiments, which
induced a polymerization of actin and tubulin
with formation of cell membrane protrusions.
Based upon the findings presented here, we
suggest that the v3 splice variant of human TrxR1
is likely to have a highly specialized expression
regulation and functional role in specific human
cells and tissues.
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1 ABBREVIATIONS
α-v3, peptide antibodies raised against part of the Grx domain of v3; GFP, green fluorescent protein; Grx,
glutaredoxin; TGR, human thioredoxin glutathione reductase encoded by the TXNRD3 gene; Trx,
thioredoxin; TrxR, thioredoxin reductase; TrxR1, thioredoxin reductase 1; TrxR2, human mitochondrial
TrxR isoenzyme encoded by the TXNRD2 gene; TXNRD1_v3, splice variant of human TrxR1 encoded
by the ß1 transcript of the TXNRD1 gene; v3-GFP, fusion construct of v3 fused at its N-terminal end to
GFP; v3(Grx)-GFP, fusion construct of the Grx domain of v3 fused at its N-terminal end to GFP; v3,
short form notation for the human TrxR1 splice variant protein TXNRD1_v3
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FIGURE LEGENDS
Scheme 1. Overview of the alternatively spliced transcripts of the TXNRD1 gene studied here.
Transcription of the α-transcripts is initiated at the major core promoter located upstream of exon I
whereas an alternative promoter upstream of exon β-VIII regulates transcription of the β1 splice variant.
The β1 transcript is translated into the third isoform of TrxR1 (TXNRD1_v3, or v3) containing an
atypical N-terminal glutaredoxin (Grx) domain fused to the common TrxR1 module. Arrowheads
connected by a dotted line indicate primer pairs used to identify the respective splice variant and the
length of the amplified fragment is given in parentheses. The dashed part of exon I shown in this scheme
in transcripts α7,α8 indicates an alternative splice donor site within that exon, resulting in either α7,α8
encoding TXNRD1_v1 or α1,α2 encoding TXNRD1_v2. Filled exons of larger width indicate the open
reading frame (ORF) of each transcript. The common TrxR1 module is shown in green, the unique part of
the Grx domain of the β1 transcript is indicated in red, and the sequences shared between the Grx domain
and the N-terminal part of TXNRD1_v2 are hatched. The scheme is drawn approximately to scale, as
indicated in the figure. Note that the complete TrxR domain is encoded by additional exons downstream
of exon V. The scheme has been modified from an earlier report, to which the reader is referred for
further information including sequences and accession numbers (7).
Figure 1. Expression of v3 in testis, in particular the Leydig cells. (A) A Northern blot using a v3-
specific probe, containing the first three exons of the Grx domain unique to v3, identified a single
transcript in testis while all other analyzed tissues were negative. (B) Specific analysis of first-strand
cDNA using the Fβ-VIII/R2 primer pair (see Scheme 1) showed a PCR-product corresponding to 468 bp
with the strongest expression in testis and weak expression in heart, liver, kidney, pancreas, spleen and
ovary. (C-D) Immunohistochemical staining of tissue sections from testis, derived from a donor in his
mid 40’s are shown. (C) A polyclonal antibody, α-v3, generated against a synthetic peptide contained in
the unique part in the Grx domain of v3, showed a strong signal in the interstitial Leydig cells. D shows a
pre-absorption control done with the synthetic peptide used to generate the antibody, diminishing the
signal in Leydig cells and illustrating the specificity in the staining pattern. (E-F) Testis tissue sections
taken from the Human Protein Atlas, according to its academic usage permission (see (13) and
www.proteinatlas.org), are shown for comparison. Those testis sections were derived from a 26-year-old
male (E) and a 68-year-old male (F) and stained with a commercial mouse monoclonal α-TrxR1 primary
antibody (Santa Cruz, cat. # sc-28321) generated against amino acids 71-340, encoded by exon V
(Scheme 1), of the TrxR1 domain. Hence, that antibody binds all three isoforms TXNRD1_v1-3 and
staining is seen in Leydig cells as well as Sertoli cells and seminiferous tubules.
Figure 2. Expression of TrxR1 splice variant in different cancer cell lines. (A) First-strand RT-PCR of
various cancer cell lines was performed to identify the potential concomitant transcription of different
splice variants of TrxR1 (see Scheme 1). The β1 variant showed a distinct transcription pattern in some of
the cell lines while the α7,α8 transcripts were expressed at a high level in all of the investigated cancer
cell lines and α1,α2 was weakly but consistently detected. (B) PCR results using cDNA from treated
HeLa cells showed an upregulation of β1 by estradiol or testosterone; Estradiol (1 µM); Testost.,
testosterone (0.1 µM); No FCS, medium without FCS; HU (10), hydroxyurea (10 µM); HU (100),
hydroxyurea (100 µM); Pos. Ctrl., positive control; Neg. Ctrl., negative control. The cDNA of v3 in a
plasmid was used as a positive template control.
Figure 3. No co-localization of v3 with estrogen receptors. To analyze localization of v3 with respect
to estrogen receptors (ER), HEK293 cells were transfected with either the complete isoform v3 fused to
GFP (v3-GFP) and stained for ERα (A) or transfected with the Grx domain of v3 fused to GFP (v3(Grx)-
GFP) and stained for ERβ (B) under treatment of estrogen as described in Materials and Methods. Cells
were analyzed using an AS MDW fluorescence microscope.
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Figure 4. Dotted cytosolic and membrane-associated localization pattern of v3 compared to actin
and tubulin. The fluorescence microscope pictures show HeLa (A-B) or HEK293 cells (C-G) transfected
with either the complete isoform v3 fused to GFP (v3-GFP) or the Grx domain of v3 fused to GFP
(v3(Grx)-GFP)  and also stained for actin, tubulin and nuclei using DAPI. Cells transfected with a TrxR1-
GFP construct or the GFP protein alone were used as control (GFP control).
Figure 5. The isoform v3 leads formation of cell membrane protrusion and is followed by actin and
tubulin. (A-D) An enlargement of a cell membrane protrusion of a HEK293 cell, transfected with the
v3(Grx)-GFP construct, is given (area indicated in Fig. 4C by a dashed white box) whereas (E) shows a
three-dimensional isosurface model. v3(Grx) is shown in green, actin in red and tubulin in blue.
Movie 1. TXNRD1_v3 provokes rapid formation of cell membrane protrusions. HEK293 cells
transfected with v3-GFP were followed as live cells for one hour with a z-stack obtained every minute,
deconvolved and then combined into a single file to compose this visual recording. (the enclosed figure is
a still image from a movie provided as supplemental data on JBC On-line).







